Condition: Ebola Virus Disease · Sponsor: Institute of Tropical Medicine, Belgium
The goal of this randomized controlled trial is to investigate whether individuals in DRC previously vaccinated with Zabdeno/Mvabea® or Ervebo® vaccine schedules against Ebola virus can be safely and adequately boosted with homologous or heterologous vaccine schedules. Participants will be randomized to receive either a homologous or heterologous vaccine schedule and will be asked to come to the clinic at prespecified timepoints over a period of 6 months to collect blood samples for comparison of immunological responses against Ebola virus between both schedules. Safety and tolerability of the vaccines will be evaluated by recording Adverse Events (AE's) and grading physical and vital signs evaluations.
This description comes directly from the study's public registry record.
Wim Adriaensen, Prof. · +32(0)33455909 · wadriaensen@itg.be
Selien Oostvogels Oostvogels · soostvogels@itg.be
Always discuss trial participation with your own doctor first.
| Institut National de Recherche Biomédicale (INRB) | Goma, Democratic Republic of the Congo | Not Yet Recruiting |
| Institut National de Recherche Biomédicale (INRB) | Kinshasa, Democratic Republic of the Congo | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06126822